There are 10 papers on A1C in aging research: 2 trials and 6 observational studies in people, 2 reviews.
10 papers study it13 findings
2 new papers in 30 daysSee all 10 papers on A1C
“Greater A1C lowering and weight loss was observed in patients without prior GLP1-RA treatment compared to those switched to tirzepatide from GLP1-RA.”
- Human trial2
- Humans6
Interventions
6Tirzepatide
downin humans4
4 studies
Tirzepatide
downin humans4
Tirzepatide is linked with lower A1C in humans (added to concomitant insulin therapy in patients with type 2 diabetes).
Humansadded to concomitant insulin therapy in patients with type 2 diabetesn = 135
Tirzepatide is linked with lower A1C in humans (mean reduction 1.02 ± 1.48%).
Humansmedian 10.4 monthsn = 612
Tirzepatide decreases A1C in humans (lowered by 1.7-2.4% from baseline).
Review
Tirzepatide decreases A1C in humans.
Review
GLP-1 receptor agonists
downin reviews1
1 study
GLP-1 receptor agonists
downin reviews1
GLP-1 receptor agonists decrease A1C (obesity and type 2 diabetes) (A1c levels below 5.7%).
Reviewobesity and type 2 diabetes
Continuous glucose monitoring
downin humans1−0.4% greater reduction
1 study
Continuous glucose monitoring
downin humans1−0.4% greater reduction
Continuous glucose monitoring is linked with lower A1C in humans (compared with non-CGM users) (0.4% greater reduction).
Humanscompared with non-CGM users
Physical activity
no changein humans1
1 study
Physical activity
no changein humans1
Physical activity was not clearly linked with A1C in humans (prediabetes and overweight/obesity; adjusted models; reference <75 min/week) (No significant association across A1C reduction thresholds ≥0.1% to ≥0.4%).
Humansprediabetes and overweight/obesity; adjusted models; reference <75 min/weeksix 75-min weekly increments, ranging from <75 to >375 min12 monthsn = 209
Sulfonylureas
downin humans1
1 study
Sulfonylureas
downin humans1
Sulfonylureas are linked with lower A1C in humans (sulfonylurea alone in young-onset type 2 diabetes; usual-onset showed an increase) (-0.08% (young-onset) vs +0.06% (usual-onset)).
Humanssulfonylurea alone in young-onset type 2 diabetes; usual-onset showed an increase
Metformin
downin humans1
1 study
Metformin
downin humans1
Metformin is linked with lower A1C in young-onset type 2 diabetes, compared with usual-onset (-0.15% (young-onset) vs -0.17% (usual-onset)).
Humansin young-onset type 2 diabetes, compared with usual-onset
Associations
4Spontaneous alpha power
downin humans1
1 study
Spontaneous alpha power
downin humans1
A1C is associated with spontaneous alpha power in humans (cognitively normal aging adults).
Humanscognitively normal aging adultsinferior frontal and temporal cortexn = 43
Spontaneous delta power
downin humans1
1 study
Spontaneous delta power
downin humans1
A1C is associated with spontaneous delta power in humans (biomarker-positive participants on the Alzheimer’s disease spectrum).
Humansbiomarker-positive participants on the Alzheimer’s disease spectrumfrontotemporal and inferior parietal cortexn = 37
Weight loss
downin humans1OR 6.36–9.49
1 study
Weight loss
downin humans1OR 6.36–9.49
Weight loss is associated with A1C in humans (prediabetes and overweight/obesity; compared with no weight loss) (OR range 6.36–9.49 for A1C reductions ≥0.1% to ≥0.4%).
Humansprediabetes and overweight/obesity; compared with no weight loss>5% weight loss12 monthsn = 209
Tirzepatide
downin humans1
1 study
Tirzepatide
downin humans1
Tirzepatide is associated with A1C in humans (greater in GLP1-RA-naive patients than in patients switched from GLP1-RA).
Humansgreater in GLP1-RA-naive patients than in patients switched from GLP1-RA
Funding
3 grants since 2018National Institute of Diabetes and Digestive and Kidney Diseases$1.3MUS Department of Veterans Affairs
Hemoglobin A1C Variability as a Risk Factor for Diabetes Complications
National Institute of Diabetes and Digestive and Kidney DiseasesHarvard Medical School$520K2019–2023
Hemoglobin A1c Variability and Adverse Health Outcomes
US Department of Veterans AffairsVA Boston Healthcare System2017–2019
Portable, affordable, quantitative microchip electrophoresis for hemoglobin A1C testing
National Institute of Diabetes and Digestive and Kidney DiseasesHemex Health$225K2018–2021